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Identity 
Other names: Uterine fibroids; Uterine fibromyoma; 
fibroids; fibroma; fibroleiomyoma; myoma 
Note: Uterine Leiomyomata (UL), benign smooth 
muscle tumors of the uterus, are the most common 
pelvic tumors in women. UL are symptomatic in 
approximately 25% of reproductive age females and 
are the primary indicator for hysterectomy in the 
United States accounting for over 200,000 procedures 
annually. Careful pathologic examination of the uter s 
shows over 75% of reproductive age females have UL 
with the average affected uterus containing six to seven 
fibroids. UL are frequent in women older than 30 years 
of age, very rare in woman below the age of 18, and 
tend to regress after menopause. Rarely are UL 
estimated to become malignant leiomyosarcoma. They 
are steroid-hormone dependent tumors and especially 
sensitive to estrogen and progesterone actively 
impacting their overall growth and development. 
See WebPath leiomyoma, leiomyomata, and 
degeneration. 
Classification 
Note: Classification of leiomyomas is based on 
location within the uterus (see figures below). 
Uterine Layer 
- Subserous: located just beneath the serosal surface. 
They grow out toward the peritoneal cavity, and canbe 
sessile (broad-based) or pedunculated (attached to the 
surface by a narrow stalk). The pedunculated ones may 
attach themselves to adjacent structures like the bowel, 
omentum or mesentery, and develop a secondary blood 
supply, loosing its primary uterine blood supply 
(parasitic leiomyoma). Subserous leiomyomas may also 
extend into the broad ligament (intraligamentary 
leiomyomas). 
- Intramural: are the most common type of UL, found 
primarily within the thick myometrium. 
- Submucous: are the most symptomatic form of UL, 
located beneath the endometrium (uterine mucosa). 
Like subserosal UL, they may be sessile or 
pedunculated. The pedunculated nodules may protrude 
through the cervical os, and may undergo torsion, 
infarction, and separation from the uterus. Submucous 
leiomyoma are often associated with an abnormality of 
the endometrium, resulting in a disturbed bleeding 
pattern. 
Clinics and pathology 
Epidemiology 
Ethnic predisposition studies show leiomyomas are 
more frequent (from three to nine fold) in women of 
African origin than women of other ethnic groups. 
African American women are reported to have an 
earlier age of UL diagnosis, larger and more abundant 
tumors, greater symptom severity and higher rates of 
hysterectomy. Risk factors for UL include early age of 
menarche, nulliparity, oral contraceptive use and 
obesity. 
Clinics 
Clinical presentation depends upon size, location and
number of lesions. UL may occur singly but often are
multiple, with variations in size. They may manifest 
with profuse menstrual bleeding, pelvic pain and 
pressure, and reproductive dysfunction causing 
significant medical and social morbidity. UL may be a 
cause of pregnancy complications, such as abortion, 
hemorragic degeneration, disseminated intravascular
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 (Source of images: http://www.fibroids.net/aboutfibroids.html#basic ) 
 
coagulation, hemoperitoneum, premature rupture of 
membranes, dystocia, inversion of the uterus, 
antepartum and postpartum hemorrhage, breech 
presentation, placental abruption and postpartum 
sepsis. They are steroid-hormone dependent and have 
high estrogen concentrations, elevated numbers of 
estrogen receptors and more bound estrogen. UL 
increase in size when exposed to high estrogen levels, 
such as during the reproductive years and diminish in 
the presence of low estrogen levels, following 
menopause or during GnRH agonist therapy. Having 
more progesterone receptors than normal myometrium, 
UL also grow in the presence of high progesterone 
concentrations. Growth hormone (GH) and prolactin 
(PRL) are thought to promote UL growth, but require 
further investigation. 
Pathology 
Leiomyomas are dense, well-circumscribed nodules 
consisting of myometrial-derived smooth muscle cells  
and extracellular matrix (e.g. collagen, fibronectin, 
proteoglycan). The cut surfaces are white to tan in 
color, with a whorled trabecular pattern. The 
appearance is often altered by degenerative changes. 
Microscopically, they consist of whorled, anastomosing 
fascicles of uniform, spindle-shaped, smooth muscle 
cells. Cells have indistinct borders and abundant 
fibrillar, eosinophilic cytoplasm. The nuclei are 
elongated and have finely dispersed chromatin. They 
may show areas of hemorrage, as well as cystic 
degeneration and microcalcification in a minority of 
lesions. 
Despite the variety in the histologic subtypes of 
leiomyomas, all are grossly similar. In addition to 
histologically typical UL, several other specific 
subtypes are distinguished, some of which are very 
rare:  
- Cellular leiomyoma (composed of densely cellular 
fascicles of smooth muscle with little intervening 
collagene). 
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- Atypical leiomyoma (containing atypical cells, 
clustered or distributed through the lesion). 
- Epithelioid leiomyoma (composed of round or 
poligonal cells rather than spindle-shaped. This 
subtype includes leiomyoblastoma, clear cell 
leiomyoma, plexyform leiomyoma). 
- Myxoid leiomyoma (containing abundant 
amorphous myxoid substance between the smooth 
muscle cells). 
- Vascular leiomyoma (containing dense 
proliferations of large, caliber, thick-walled 
vessels). 
- Lipoleiomyoma (consisting of a mixture of mature 
adipocytes and smooth muscle cells). 
- Leiomyoma with tubules (containing tubular 
structures). 
- Benign metastasizing leiomyoma (occurrence of 
multiple smooth-muscle nodules, most often 
located in the lung after previous hysterectomy). 
Microscopic pathology: see WebPath leiomyoma  
Treatment 
Only UL that are symptomatic, enlarge rapidly, or pse 
diagnostic problems, are typically removed. The 
traditional and most definitive treatment for UL is
hysterectomy (surgical removal of the uterus). 
Myomectomy is another surgical option for women 
with fewer and smaller tumors wanting to remove UL, 
yet maintain fertility. Uterine Artery Embolization 
(UAE) is a radiological alternative especially effective 
at treating intramural UL that are difficult to access 
surgically, yet the impact on pregnancy and future 
fertility is unclear. Despite being expensive and having 
limited availability, a noninvasive thermoablative 
procedure known as MRI-guided focused ultrasound 
(MRIgFUS) has recently been shown to target specific 
UL effectively and decrease recovery time. Certain 
medications, such as gonadotropin releasing hormone 
agonists (GnRHa), can alleviate UL symptoms by 
decreasing estrogen levels to a menopausal-like stat . 
However, current medical therapies cannot prevent 
recurrence. 
Genetics 
Note: Familial aggregation and twin studies support the 
heritability of these tumors. First-degree relatives of 
women with UL are 2.5 times more likely to develop 
these tumors than women with unaffected relatives, 
suggesting a possible predisposition. Glucose-6-
phosphate dehydrogenase isoenzyme and androgen 
receptor polymorphism studies have demonstrated that 
UL develop as independent clonal lesions. 
Accordingly, UL may be found with different 





Note: Approximately 40% of cytogenetically 
investigated cases show abnormal karyotypes, usually 
with single or few changes. Rarely, they may show 
complex karyotypes. The cytogenetic heterogeneity of 
UL can be attributed to various clonal chromosomal 
changes such as translocations, deletions and trisomie . 
Subgroups of common cytogenetic rearrangements 
include a translocation between chromosomes 12 and 
14, trisomy 12, deletions of portions of the long arms of 
chromosomes 3 or 7 and the short arm of chromosome 
1, rearrangements of the short arm of chromosome 6 
and rearrangements of chromosomes 1, 3, 10, 13 and 
X. Although the initiating event for tumorigenesis 
remains unknown, the variety of cytogenetic 
abnormalities displayed in UL suggests multiple 
genetic pathways may be involved. 
Correlations between cytogenetics and clinical 
phenotype:  
- Myoma location/incidence of abnormal karyotype: 
- intramural - 35%; 
- subserosal - 29%; 
- submucosal - 12%. 
- Type of chromosome abnormality/ tumor mean size: 
- tumors with normal karyotype - 5.4 cm; 
- tumors with del(7q) - 5cm; 
- tumors with t(12; 14) rearrangements - 8.5 cm. 
Cytogenetics morphological 
t(12;14)(q14-15;q22-24) subgroup. 
It is found in approximately 20% of the abnormal cases. 
The t(12;14)(q14-15;q22-24) translocation is the first 
chromosome alteration reported in uterine leiomyoma. 
It may be observed as the sole cytogenetic abnormality, 
or together with other clonal changes, such as del(7q). 
The chromosome segment 12q14-15 may be rearranged 
with other translocation partners (such as chromosoe  
X, 2, 8, 9, 10, 22) or may undergo pericentric inversion. 
Myoma cells with this abnormality are responsive to 
the immortalization by the 'early region' of the SV40 
genome. 
t(12;14)(q14-15;q22-24) subgroup - molecular 
findings: 
In this subgroup dysregulation of the HMGA2 
(formerly HMGIC) gene located at 12q15 has been 
observed.  
Chromosome 12 breakpoint is often located 10 kb up to 
100 kb 5' to HMGA2, and in a majority of cases there 
is no fusion transcript. 
However, in a number of cases the gene is altered: 
- case with pericentric inversion: HMGA2 exon 3 is 
fused to ALDH2 exon 13 (12q24.2). 
- case with apparently normal karyotype: HMGA2 
exon 3 is fused to retrotransposon-like sequences 
RTVLH 3' LTRs. 
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- case with complex karyotype including 
chromosome 12 and 14 rearrangements: 
cumulative dosage effect of a RAD51L1/HMGA2 
fusion and RAD51L1 loss. 
- case without cytogenetic analysis: HMGA2 exon 3 
is fused to COX6C exon 2 (8q22-23). 
- cases without cytogenetic analysis: HMGA2 exon 
2 or 3 is fused to RAD51L1 exon 7 (14q23.3-24). 
- cases without cytogenetic analysis: HMGA2 
isoforms due to aberrant alternative splicing. 
- case without cytogenetic analysis: HMGA2 exon 2 
is fused to the 3' portion of the HEI10 gene, 
located at 14q11. 
del(7)(q22-32) subgroup. 
It is found in approximately 17% of the karyotypically 
abnormal cases. 
It may be observed as the sole cytogenetic abnormality, 
or together with other changes. It is often associated 
with t(12;14) or alterations of the chromosome segmnt 
12q14-15. 
The del(7q) clone is almost invariably found together 
with a normal clone. 
A few cases with translocations involving 7q22 have 
been described. 
Myoma cells with del(7q) are not responsive to the 
immortalization by the 'early region' SV40 virus, unless 
they also contain 12q14-15 abnormalities. 
Myoma with del(7q) tend to be smaller than those 
showing 12q14-15 abnormalities. 
del(7)(q22-32) subgroup - molecular findings:  
Conflicting minimal deletion regions have been 
proposed by multiple loss-of-heterozygosity (LOH) 
analyses using polymorphic microsatellite markers. The
resultant tumor suppressor candidate genes, including 
CUTL1, ORL5L, PAI1, PCOLCE and LHFPL3, were 
not consistently altered in expression. Most recently, a 
study using 7q tiling path CGH microarrays confined 
the minimal deletion region to 2.79 Mb at 7q22 and 
also proposed a second region of loss at 7q34. 
However, no pathogenic coding variation was detected 
in the genes encompassed by the proposed region. At 
the present time the tumor-suppressor gene(s) 
responsible for del(7q) fibroid growth has not been 
identified despite much effort. This raises the 
possibility that a mechanism other than loss of tumor-
suppressor gene function could be responsible for 
development of del(7q) fibroid tumors. 
6p21 rearrangement subgroup. 
Aberrations of the 6p21, including deletions, 
translocations, and inversions are found in less than 
10% of the abnormal cases. 
6p21 rearrangements may be observed as the sole 
cytogenetic abnormality, or together with other clonal 
changes. Simple and complex rearrangements of 6p21 
have been observed. Complex rearrangements are 
sometimes definable only by FISH analysis. 
The most frequent translocation partners are 
chromosomes 1, 2, 4, 10 and 14 with rearrangements 
including t(1;6)(q23;p21), t(6;14)(p21;q24), and 
t(6;10)(q21;q22). 
6p21 rearrangement subgroup - molecular findings: 
HMGA1 (formerly HMGIY) (6p21.3) is the pathogenic 
sequence. No hybrid gene has been described yet. 
A genomic PAC clone containing the gene spans the 
6p21.3 breakpoint. The breakpoint seems to be 
extragenic, located within an 80 kb region 3' of 
HMGA1. 
One case of aberrant transcript with truncation of 1295 
bp from the 3' UTR has been described. 
del(1)(p11p36) subgroup:  
This subgroup is characterized by an almost complete 
loss of the short arm of chromosome 1. 
Rearrangements are often observed with additional 
cytogenetic abnormalities such as the loss of 
chromosomes 19 and/or 22. 
del(1p) subgroup - molecular findings: 
Transcriptional profiles with loss of 1p in UL resemble 
those of leiomyosarcoma suggesting a similar pathway 
for tumorigenesis. LOH analysis of polymorphic 
microsatellites confirmed deletion of the 1p region. 
Karyotypic representation of specific chromosomal aberrations 
in UL. (Modified from Lobel et al., 2006). 
(A): t(6;14)(p21;q24) has been observed in UL and other 
mesenchymal tumors, and implicates HMGA1 at band 6p21. 
(B): Tumors with del(7)(q22q32) abnormalities are generally 
smaller in size than tumors with t(12;14) translocations.  
(C): A minor cytogenetic subgroup of UL, t(10;17)(q22-
q24;q21-q22), has been observed in a subset of tumors and 
involved the MORF gene at the 10q22 breakpoint.  
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Genes involved and Proteins 
Note: Elevated levels of HMGA expression have been 
observed in tumor cells and during embryonic tissue 
development suggesting that HMGA proteins influence 
cell growth. Dysregulation of HMGA2 (12q15) and 
HMGA1 (6p21.3) genes have been observed in uterine 
leiomyomas. Mechanisms leading to dysregulation 
include fusion transcript formation, HMGA2 
truncation, and disruption of HMGA2 regulatory 
sequences. 
It has been suggested that the expression of HMGA1 
and HMGA2 is controlled by regulatory elements 
within their 3'UTR: luciferase assays with HMGA1 
3'UTRs of different length show an increase in 
luciferase activity by truncation of the 3'UTR. Of 
interest, HMGA1 and HMGA2 have been shown to 
contain multiple sites in their 3'UTRs predicted to be 
targets of micro RNAs, which likely play an importan  
role in their regulation. 
UL are also associated with insufficiency of FH 
(fumarate hydratase). FH encodes fumarase, involved 
in the key metabolic pathway of the Krebs cycle and 
may play a role in tumor development as a tumor 
suppressor gene. Structural rearrangements of 1q42. 
leading to missense mutations and various deletions 
(i.e., protein-truncating, large germline and in-frame) of 
FH can lead to haploinsufficiency and subsequent 
absent expression if the other FH allele is mutated 
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